Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials

被引：3
作者：
Derosa, Giuseppe [1 ]
Salvadeo, Sibilla [2 ]
Cicero, Arrigo F. G. [2 ]
机构：
[1] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy
[2] Univ Bologna, G Descovich Atherosclerosis Study Ctr, D Campanacci Dept Clin Med & Appl Biotechnol, Bologna, Italy
来源：
CURRENT CLINICAL PHARMACOLOGY | 2006年 / 1卷 / 01期
关键词：
Hypertension; DM; ACE-inhibitor; Diuretic; Calcium-channel blocker; Angiotensin-receptor blocker;
D O I：
10.2174/157488406775268237
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hypertension (blood pressure (BP) > 140/90 mmHg) is a common comorbidity of type 2 DM (DM) and a major risk factor for macro-and microvascular complications. To review the effectiveness of different antihypertensive drugs in reducing BP, and diabetic complications in patients with DM, we analysed clinical trials, reviews and reports, published in Cochrane Library and PubMed from 1991 to 2004. Evidences suggest that optimal control of hypertension complications is obtained in diabetic patients when BP values are < 130/80 mmHg. Different drug classes result useful to obtain this target BP, but their effects on different metabolic and non-metabolic aspects have to be taken in account and a flexible approach according to individual response to different regimens is essential.
引用
收藏
页码：21 / 33
页数：13
相关论文
共 35 条
[1]  
Adler AI, BMJ
[2]  
*AM DIAB ASS, 2004, DIABETES CARE S1, V27, pS15
[3]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[4]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [J].
Curb, JD ;
Pressel, SL ;
Cutler, JA ;
Savage, PJ ;
Applegate, WB ;
Black, H ;
Camel, G ;
Davis, BR ;
Frost, PH ;
Gonzalez, N ;
Guthrie, G ;
Oberman, A ;
Rutan, GH ;
Stamler, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1886-1892
[7]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[8]   Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: A 12-month, randomized, double-blind study [J].
Derosa, G ;
Cicero, AFG ;
Bertone, G ;
Piccinni, MN ;
Fogari, E ;
Ciccarelli, L ;
Fogari, R .
CLINICAL THERAPEUTICS, 2004, 26 (08) :1228-1236
[9]   Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study [J].
Derosa, G ;
Ragonesi, PD ;
Mugellini, A ;
Ciccarelli, L ;
Fogari, R .
HYPERTENSION RESEARCH, 2004, 27 (07) :457-464
[10]  
Estacio RO, 2000, DIABETES CARE, V23, pB54
1234